Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD8RU0)

Drug Name
SEphB4-HSA Drug Info
Indication
Disease Entry ICD 11 Status REF
Kaposi sarcoma 2B57 Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMD8RU0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Ephrin type-B receptor 2 (EPHB2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BVD-523 DMNB4XK Melanoma 2C30 Phase 2 [4]
KO-947 DMZMSBI Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
MK-8353 DMLCTI5 Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
AMP-PNP DMTOK1D Discovery agent N.A. Investigative [5]
PMID23489211C20 DMDYC4J Discovery agent N.A. Investigative [6]
PMID19788238C66 DMCVJK9 Discovery agent N.A. Investigative [7]
SNEWIQPRLPQH DMYUH62 Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ephrin type-B receptor 2 (EPHB2) TTKPV6O EPHB2_HUMAN Inhibitor [3]

References

1 ClinicalTrials.gov (NCT03993106) A Study of sEphB4-HSA in Kaposi Sarcoma. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT01642342) Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors. U.S. National Institutes of Health.
3 National Cancer Institute Drug Dictionary (drug name SEphB4-HSA).
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
6 Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
7 Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
8 Three-dimensional structure of the EphB2 receptor in complex with an antagonistic peptide reveals a novel mode of inhibition. J Biol Chem. 2007 Dec 14;282(50):36505-13.